Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28527043 | 0.89 | ALDH1A1 (0.34) | MEN1ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18613472 | 0.87 | MAPT (0.33) | MEN1ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5605635 | 0.86 | ALDH1A1 (0.34) | MEN1ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL28527045 | 0.86 | TSHR (0.36) | MEN1ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22125604 | 0.85 | ALOX5 (0.37) | ALOX5PGAM1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL24822046 | 0.84 | TOP2A (0.36) | KMT2ASMN1; SMN2 | |
| SCHEMBL18613473 | 0.83 | TSHR (0.34) | ALDH1A1CYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL22125713 | 0.81 | ALOX5 (0.35) | ALOX5PGAM1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL22125759 | 0.80 | ALOX5 (0.36) | ALOX5PGAM1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL20624632 | 0.79 | ELANE (0.32) | ALDH1A1CYP1A2CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072138-A1 | NRTI THERAPIES | THE JOHNS HOPKINS UNIVERSITY | 2022-03-10 | — | — | US | disclosed |
| CN-113474008-A | NRTI therapy | 利物浦大学 | 2021-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072138-A1 | NRTI THERAPIES | TK1, PNP, TYMP | ALOX5 910/4885PGAM1 546/4885MEN1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.